NCT03519230 2026-03-16Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerBeOne MedicinesPhase 3 Active not recruiting224 enrolled
NCT04164199 2026-03-16Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesBeOne MedicinesPhase 3 Enrolling by invitation430 enrolled